Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...